FDA vaccine chief signals major overhaul after internal memo on child deaths

1 December 2025

US Food and Drug Administration staff are bracing for a sweeping shift in vaccine oversight after Vinay Prasad, head of the agency’s Center for Biologics Evaluation and Research (CBER), said the agency will regulate vaccines in the same way it regulates other drug classes.

The internal note, prompted by an analysis he says ties at least ten child deaths to COVID-19 shots, marks the most dramatic intervention by a senior official since Robert Kennedy Jr became Health and Human Services Secretary (HHS) in January.

In the memo, Dr Prasad claimed that “no fewer than 10” deaths among 96 reports submitted to the Vaccine Adverse Event Reporting System (VAERS) between 2021 and 2024 were related to vaccination, while arguing the true total could be higher. He offered no clinical details, timelines or manufacturer information, and the findings have not been peer-reviewed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >




Today's issue

Company Spotlight



More Features in Pharmaceutical